

January 31, 2006

Dear Colleagues:

We are delighted to announce that Specialty Laboratories, Inc. has completed its merger with AmeriPath, Inc., a leading provider of anatomic pathology and molecular diagnostics headquartered in Palm Beach Gardens, Florida (please see attached announcement). Specialty Laboratories will remain a distinct operating division and retain its name and corporate identity. Our state-of-the art facility in Valencia, California will become the Esoteric Testing Division Headquarters for the newly combined organization.

Our complementary areas of expertise in advanced clinical testing and molecular diagnostics and our expanded bi-coastal geographic presence, will allow us to serve you more completely and more effectively, so you can provide enhanced patient care in the communities you serve.

R. Keith Laughman, who joined AmeriPath in April, 2005 as President for Esoteric Services, has an accomplished 30-year record with the Mayo Clinic. As President of Specialty Laboratories, Keith will lead the new organization to ensure that clients receive maximum benefits from the combined expertise of the two companies. We have begun transferring tests and technology to leverage our shared medical and scientific expertise. That means we will soon provide you with even more comprehensive testing for more decisive information and more efficiency in meeting your patient care needs.

We anticipate many exciting enhancements in 2006 and beyond, including:

- A collective process for ordering and reporting both clinical and anatomic pathology testing services to expedite testing for enhanced patient care

- Additional clinical and pathology outreach partnership solutions to help support your organization's growth and position in the community


- A single-source for both clinical and anatomic pathology laboratory services and cutting-edge molecular diagnostics

This is an exciting time in medicine, particularly laboratory medicine and pathology. Significant scientific discoveries in areas such as genomics and molecular diagnostics are providing pathways to personalized patient care. Our strategic relationship with Molecular Profiling Institute, Inc. (MPI), a subsidiary of Translational Genomics Research Institute (TGen) means we can offer assays to help physicians treat patients with individualized management plans. Look to *Specialty* to be first to offer new, cutting-edge genetic tests that will enhance patient care and build your image as a leading authority within your medical community and help position your organization for growth.

We hope you are as enthusiastic as we are about the merger. We believe it will help *Specialty*, known for helping doctors help patients, accomplish its goal to support local pathology and community-based medicine by partnering with hospitals to reduce costs of episodes-of-care while helping physicians to improve overall patient care.

Our new organization is poised to help you as we embrace the future together.

Sincerely,



James B. Peter, M.D., Ph.D.  
Founder and Director of Research and Development, Specialty Laboratories

cc: R. Keith Laughman, President, Specialty Laboratories  
Vicki DiFrancesco, Senior Vice President, Sales and Marketing, Specialty Laboratories